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ABSTRACT
Mycobacterium tuberculosis (Mtb) is the pathogen that causes Tuberculosis (TB) and is
responsible for an average of 1.5 million deaths annually. Although a treatment regimen does exist,
Multi-Drug Resistant (MDR-TB) and eXtremely Drug Resistant (XDR-TB) TB strains are becoming
a more prevalent concern partly due to failure of patient compliance with the current six to nine
month drug treatment regimen. The current diagnostic methods are not able to identify these MDR
and XDR-TB strains efficiently therefore more effective point-of-care (POC) diagnostics and drug
susceptibility testing (DST) are urgently needed to detect drug resistance and facilitate prompt,
appropriate treatment plans. In order to detect TB and efficiently identify drug resistance, this
project seeks to develop a novel diagnostic technology based on deoxyribozyme (DNAzyme)
sensors.
The overall goal of this project is to create an assay which combines Polymerase Chain
Reaction (PCR) and DNAzymes to identify drug resistance conferring Single Nucleotide
Polymorphisms (SNPs). To safely test the ability of DNAzyme sensors to detect SNPs indicative of
multi-drug resistant TB, we have constructed a panel of drug resistant (drugR) nonpathogenic M.
bovis BCG. We have designed a multiplex PCR that amplifies 6 chromosomal regions of the genome
necessary for the species specific detection of TB and determination of a drug susceptibility profile
based on the presence of SNPs. To improve the sensitivity and selectivity of the detection and DST
of Mtb, we have designed and optimized DNAzyme sensor assays combined with multiplex PCR
analytes that will enable the rapid, POC detection of drug resistance. This work aims to develop
novel tools for the prompt and specific diagnosis of TB allowing for the implementation of an
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effective treatment regimen that will ultimately lessen transmission and control the emerging global
threat of MDR and XDR-TB.
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INTRODUCTION
Mycobacterium tuberculosis (Mtb) is the pathogen that causes Tuberculosis (TB). One-third of
the world’s population is currently infected with TB and it causes an average of 1.5 million deaths
annually [1]. TB is spread through aerosolized droplets expelled from the lungs of an infected
individual through talking, coughing, or sneezing wherein it may travel to the lungs of a new host
and reside in pulmonary tissue [2]. Upon infection with Mtb, a patient can develop either the active
or latent form of the disease. Active TB occurs when the body fails to control Mtb within alveolar
macrophages and can result in pulmonary damage and dissemination to other areas of the body,
both of which may ultimately result in death [3]. Individuals with active TB are infectious, will
present with symptoms, and may test positive in a sputum smear microscopy test. Symptoms include
a chronic cough, chest pain, fatigue, and weight loss [4]. Approximately 2 million people (or 90% of
patients infected with Mtb) are latently infected with Mtb [5]. Latent TB infections result when the
body effectively contains, but does not clear the infection. The patient will not present with
symptoms because the bacilli become dormant within granulomas and the disease cannot be spread
to others [6, 7]. The development of the granuloma, an immune structure formed to contain the
infection, results in difficulties treating the infection [2]. Many of the currently used drugs are unable
to effectively penetrate this barrier and bacilli in the granuloma are typically characterized by a
phenotypically nonreplicative, dormant state [6, 7].
Treatment of drug-susceptible TB consists of a four drug cocktail taken over a six to nine
month period, however, due to the lengthy treatment regimen many patients fail to comply [8]. The
current first-line drugs are isoniazid and rifampicin and when those become ineffective second-line
drugs such as fluoroquinolones are used [5]. While a treatment regimen does exist, Multi-Drug
1

Resistant (MDR-TB) and eXtremely Drug Resistant (XDR-TB) TB strains are becoming increasingly
prevalent due to failure to complete the drug regimen as well as the development of antibiotic
tolerance. In 2012, approximately 450,000 people were diagnosed with MDR-TB and there were
approximately 170,000 deaths due to MDR-TB that year [1]. Of those people with MDR-TB, 9% of
the cases were XDR-TB [4]. Treatment for drug resistant tuberculosis is even more expensive,
difficult to administer, accompanied by dangerous side effects, and requires a prolonged treatment
of 18 to 24 months [5]. Due to these factors, noncompliance with treatment and mortality rates are
even higher among these patients than those with drug-susceptible TB [1]. Single nucleotide
polymorphisms (SNPs) in the drug targets of the TB genome are the major cause underlying the
development of drug resistance [9]. Other mechanisms that may confer resistance occur through
mutations that disrupt pro-drug activation or lead to u p-regulation of the target gene [5].
Currently we rely on suboptimal diagnostic technologies for the detection of Mtb which
include sputum smear microscopy, culture based testing, and molecular diagnostics such as lineprobe assays and RT-PCR techniques like the GeneXpert. Sputum smear microscopy is the most
common diagnostic test for TB [10]. It is ineffective due to the fact that it detects less than fifty
percent of TB cases and even less in children and patients with HIV [10]. Also sputum smear
microscopy is unable to differentiate between different mycobacterium species, such as Mycobacterium
absessus (M.abs), for example, which requires its own multi-drug treatment regimen [11]. Culturebased testing is extremely slow and presents a risk of infection to those conducting the protocol
[10]. Molecular diagnostics, including line-probe assays and RT-PCR techniques like the GeneXpert,
are the optimum methods for the detection of drug resistance, however they are not feasible due to
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the high cost, technical expertise, and requirement of expensive instruments and cold storage of
reagents which are typically not available in high burden areas [12].
Due to the limitations listed above, more efficient POC diagnostics and drug susceptibility
testing (DST) are urgently needed to detect drug resistance and facilitate prompt, appropriate
treatment plans. This project seeks to develop a novel diagnostic technology based on
deoxyribozyme (DNAzyme) sensors for detection of TB and the identification of drug resistance.
The overall goal is to create a POC assay which combines Polymerase Chain Reaction (PCR) and
DNAzymes for the identification of tuberculosis and drug resistance.
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BACKGROUND
To understand the need to create a new diagnostic assay for the detection of TB and
identification of drugR, a deeper knowledge of the pathology of the disease, the rising global threat
of drug resistance, and current diagnostic technology available will be necessary. The discussion of
methods that will be utilized for the development a novel diagnostic tool that can identify TB and its
drug susceptibility, will follow.
The Bacterium
The evolution of Mycobacterium tuberculosis dates back thousands of years ago, beginning from
tubercle bacilli in East Africa. This suggests that the pathogenic bacterium has affected the human
race from the beginning of time, coevolving with its host to survive [13]. Members of the Mtb
complex include Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium canettii, Mycobacterium
microti, and Mycobacterium bovis [13]. While they differ widely in their preferred environment,
phenotype, and pathogenicity, all cause pulmonary TB-like disease in mammals [14]. The bacteria of
the Mtb complex are 99.9% similar at the DNA level and share identical hypervariable regions on
their 16S and 23s rRNA sequences [15, 16]. Before the entire genome was sequenced, it was
proposed that M. tuberculosis went through a steep reduction in the size of its genetic variation,
otherwise known as a bottleneck, due to environmental events that date back to about 15-20,000
years ago and was thought to have evolved to the human host from Mycobacterium bovis (M. bovis), the
agent of bovine tuberculosis due to the high conservation within the species, however this is still up
for debate [17-19]. The similarity between M. tuberculosis and M. bovis has enabled the development of
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an M. bovis bacilli Calmette-Guerin (BCG) vaccine for the disease that is administered in countries
with a high burden of TB [20, 21].
M. tuberculosis is a member of the Actinomycete family and can be characterized by its
unusually thick mycolic acid-rich cell well that allows it be acid-fast stained [22]. Mtb is a slowgrowing, intracellular pathogen, whose generation time of about 15-20 hours is thought to
contribute to its virulence [22]. Mtb are exclusively mammalian pathogens, needing no
environmental reservoir [22]. The bacterial adaptations of Mtb which allow for its survival in host
immune cells have enabled it to become one of the most successful human pathogens and the
mycobacteria continues to remain a major cause of death worldwide [23].
Pathology of Tuberculosis
M. tuberculosis was the cause of White Plague of Europe in the 17th century and is still the
leading cause of death due to a bacterial infectious disease worldwide [22]. The bacterium is spread
through aerosolized, hydrophobic droplets expelled from a patient with the active disease that may
be inhaled by another host [24]. Upon reaching the alveoli, the pathogen is taken up by alveolar
macrophages and resides within the lung [24]. The macrophages, while unable to kill the
mycobacteria, are able to produce an immune response that summons more macrophages and other
immune cells to aggregate and form a granuloma, the hallmark lesion of TB [2]. The immune cells of
the granuloma form a barrier around the bacteria in an effort to prevent the spread of the pathogen
[25]. Studies have shown that the virulent mycobacteria are able to replicate within the macrophage
and eventually cause macrophage cell death by inducing TNF suppression [26]. The pathogen is able
to survive within dead and dying macrophage at the necrotic center of the granuloma [2].
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Mtb’s ability to survive and replicate in macrophages is key to its survival with the host [2].
Once internalized by the macrophage, the pathogen resides within a phagosome [2]. The
phagosomes role is to eradicate the pathogen through mechanisms such as acidification within a
lysosome, reactive oxygen and nitrogen intermediates (ROS, RNI), proteolytic activity, and
antimicrobial peptides [27]. Mtb is able to inhibit these phagosomal processes to avoid its death and
create a favorable environment for replication. Their ability to avoid acidification is due to
glycolipids known as sulfatides that prevent phagosome-lysosome fusion [28]. The cell wall of the
pathogen consists mostly of lipids, specifically mycolic acids, which form a highly impermeable shell
that prevents the deadly attack of cationic proteins, lysozyme, and oxygen radicals in the phagosome
[22]. The pathogen also manipulates the phagosome to gain access to nutrients and creates an
advantageous atmosphere for replication [27]. Mtb replicates very slowly within macrophages, which
contributes to its virulence because the immune system may not recognize the bacteria right away
[22]. The mycobacterium has also been known to infect other cell types, such as dendritic cells,
neutrophils, and adipocytes as well [29]. The high burden of the increasing number of unrestricted,
replicating mycobacteria cause the macrophage to undergo apoptosis, spreading the bacteria to new
macrophages [2]. Once the initial macrophages burst, Mtb may be taken up by other migrating cells,
such as lymphocytes and dendritic cells, which have been shown to facilitate its dissemination to
distal tissues, like the spleen, liver, and central nervous system [22]. At this stage, the lymphocytes
that come in contact with the pathogen are able to activate the immune system in an effort to
destroy the life-threatening bug [22].
If the host’s immune system is not able to control the pathogen, the TB infection progresses
to an active disease. Active TB occurs in 10% of infected patients due to immune suppressing
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circumstances like HIV-coinfection, the use of immunosuppressive drugs, re-infection, or old age,
which allows the bacilli to grow and multiply inside the host [30, 31]. Individuals with active TB are
infectious, will present with symptoms, and may test positive in a sputum smear microscopy test [6].
Symptoms include a chronic cough, chest pain, production of sputum, weight loss, and fever, and
may be fatal if not treated properly [32].
However, not everyone who breathes in the aerosolized pathogen develops the active form
of the disease. About 90% of infected individuals are able to contain the bacteria within the
granuloma in a noninfectious form known as latent tuberculosis, which is asymptomatic, sputumsmear negative, and does not pose a health threat until the immune system becomes compromised
and the TB can be reactivated [6]. The chance of reactivation creates an enormous reservoir of
infection and makes the goal of eradicating this disease seem almost unattainable.
The Challenge of Drug Resistance
Each year, approximately 8 million people become infected with TB and over 95% of deaths
due to the pathogen occur in low and middle income countries [33, 34]. Treatment regimens for
active tuberculosis consists of combination of four drugs taken daily for 6-9 months [35]. The failure
of patients to adhere to this lengthy treatment, as well as irregular drug supply and improper
prescriptions, make the global eradication of TB difficult and contribute to its drug resistance [36].
M. tuberculosis has evolved many intrinsic and molecular mechanisms that also make it
difficult to treat. It is difficult for antibiotics to penetrate the bacterium due to the impermeability of
its mostly lipid cell envelop, therefore extended treatment is needed to be effective [37]. In its latent
form, the non-replicating state of tuberculosis within the granuloma allows it to be tolerant to
7

antibiotics whose main mechanism of action is to attack the replication process of the mycobacteria
[28]. The induction of efflux pumps within the macrophage can facilitate the survival of active TB
within the granuloma, allowing antibiotic resistance to develop. [38, 39]. The localization of Mtb
within host cells in various tissue sites contributes to the poor efficacy of therapeutics. The wall of
the granuloma and poor vascularization also make it difficult for adequate levels of antibiotics
penetrate to reach the tuberculosis, enabling the pathogen to slowly develop a resistance to the subtherapeutic treatment [27].
On the molecular level, positive selection of spontaneous mutants harboring single
nucleotide polymorphisms (SNPs) are the major contributor of drug resistance [9]. In recent years,
the prevalence of drug resistant strains has been increasing, especially in China, India, and South
Africa [23]. Multidrug-resistant tuberculosis (MDR-TB) is resistant to the first-line drugs, isoniazid
(INH) and rifampin (RIF) and is caused by the inappropriate or incorrect use of antibiotics as
described above. MDR-TB can be treated with second-line drugs such as fluoroquinolones,
kanamycin, and capreomycin [35, 40]. However, second-line treatment, when available, is more
costly and time extensive leading to even greater lack of compliance. The selective pressure created
by the failure to complete the second-line treatment leads to eXtremly drug-resistant TB (XDR-TB)
which is resistant to both first-line drugs, as well as at least one fluoroquinolone (FQ) and one
second-line, injectable drug [41]. In 2013 alone, 480,000 people developed MDR-TB and 9% of
these cases were estimated to be XDR-TB [36].
Mechanism of Drug Resistance
The severity of the rising drug resistance epidemic is due, in part, to the many mechanisms
that Mtb can use to gain resistance. As mentioned above, mechanisms of drug resistance include
8

intrinsic factors such as phenotypic drug tolerance mediated by efflux pumps, characteristic of its
cell wall, and SNPs.
SNPs within the drug targets of the TB genome can confer resistance to specific first- and
second-line drugs. This project specifically focuses on the katG, inhA, rpoB, and gyrA genes as they
contain the most commonly occurring drug resistance mutations [5]. Mutations in the sequence of
katG, a catalase-peroxidase enzyme, cause decreased activation of the prodrug INH, the most widely
used first-line drug against tuberculosis, and contribute to 75-90% of the strains resistance to INH
[5, 42]. Mutations in the promoter region of the drug target gene inhA, which functions as a
NADH-dependent enoyl-acyl carrier protein, account for an additional 10% of strains resistance to
INH [5, 42]. Mutations in the beta subunit of RNA polymerase, encoded by the rpoB gene, are
present in 90% of strains that are resistant to RIF, another first-line drug used to treat TB [5, 42].
Resistance to fluoroquinolones, a second-line anti-tuberculosis drug, is conferred by
mutations in DNA gyrase, an enzyme involved in regulating the supercoiled topology of doublestranded DNA (dsDNA) [5]. DNA gyrase consists of two alpha and two beta subunits encoded by
gyrA and gyrB respectively [5]. Over 90% of fluoroquinolone resistant M. tuberculosis strains have
mutation in these two genes, contributing to XDR TB [5]. Currently other members of the Rohde
lab are developing MDR sensors for INH and RIF. This project specifically focuses on the
development of an XDR assay that will identify resistance conferring SNPs on the gyrA gene [5].
Mutations within a highly conserved area of gyrA known as the quinolone-resistance-determiningregion (QRDR) have been shown to confer fluoroquinolone resistance on TB [5]. Codons 90 and 94
of gyrA contain the most prevalent resistance-conferring mutations, particularly A90V
(GCGGTG) and D94G (GACGGC) [5]. The goal of one of the aims of this project is to
9

design sensors that will identify the D94G mutation in gyrA. The development of a molecular assay
with the ability to detect these SNPs indicative of a drugR profile could enable the rapid and efficient
treatment of TB.
Current Diagnostic Methods
Rapid and affordable POC detection of tuberculosis and drug resistance is imperative to
improve treatment and control the spread of TB. Current methods of detection include microscopy,
culture and drug susceptibility testing, as well as molecular testing [43]. Sputum smear microscopy, is
the most widely used method to detect infectious TB, especially in low and middle income countries
because it takes advantage of inexpensive equipment and materials. This diagnostic method is
accomplished through the collection and analysis of sputum specimens from persons suspected of
having TB [10]. Due to the acid-fast nature of its cell wall, tuberculosis bacilli are able to be stained
using the Ziehl-Neelson staining method and examined microscopically [22]. However, acid-fast
organisms other than M. tuberculosis may appear [10]. Less than 50% of cases are usually detected
because an excess of 10,000 microbes/mL of sputum are needed to visualize the bacilli and many
positive TB patients have been shown to have negative smears (i.e. children and co-infected-HIV
patients) because of their pauci-bacillary sputum samples (low bacilli numbers in sputum below
detection ability of assay) [10, 22]. The pathogen may also be undetectable with this method
depending on how advanced the infection is, because some Mtb lose their acid-fastness. Other
limitations of smear microscopy include its time consuming protocol and inability to detect drug
resistance [10, 44, 45]. Due to all of these factors, sputum smear microscopy can only be used as a
preliminary measure.
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The culture methods may be used in diagnosis of Mtb but further testing is needed to
differentiate Mtb from Non-tuberculosis Mycobacteria (NTM) and it requires highly technical
expertise and expensive machinery [43]. It is important to specifically identify the M. tuberculosis
species because other NTM may require their own specific treatment regimens [46]. This method is
also at a disadvantage because it can take up to 6 weeks to produce results, allowing for the
possibility of inappropriate treatment if patients are started on a typical treatment regimen before
results are obtained. If the patient is indeed infected with MDR-TB, the treatment will be ineffective
allowing the spread and amplification of drug resistant TB in the meantime [45]. Drug susceptibility
testing, through the culture-based observation of growth or inhibition in a medium containing
antituberculosis drug, can provide a definite diagnosis of drug-resistant TB but its methods are also
costly and not readily available in high burden areas [43, 47].
Molecular testing involves examining the DNA of specific genes that are known to cause
drug resistance if mutated [12]. Methods such as conventional DNA sequencing, pyrosequencing,
real-time PCR, and line-probe assays are the optimum diagnostic methods available due to their
rapid, accurate, and safe detection strategies however these techniques are still accompanied by
limitations [43]. All of the current molecular diagnostics are extremely labor intensive and expensive.
DNA sequencing and pyrosequencing require very complex machinery and costly reagents that may
not be readily available in POC environments [12]. Real-time PCR techniques such as the fully
automated GeneXpert MTB/RIF have been proven to rapidly detect the presence of M. tuberculosis
as well as identify rifampin resistance. It does so by employing multiple fluorescent molecular
beacons to detect the presence of rpoB mutations, which confer 95% of rifampin resistance [5]. Line
Probe Assays, such as the Hain Line Probe Assay MRBDRplus, employ immobilized membrane-
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bound probes that result in a color change upon binding to specific PCR products that are able to
identify mutations in the rpob, katG, and inhA genes that confer resistance to RIF and INH [5, 12].
However, both of these molecular methods can yield inaccurate results due to silent mutations,
require multiple beacons/probes, and, besides being very expensive, are not amenable for POC use
[12, 43]. The pitfalls of these current techniques reinforce the urgent need for more efficient
diagnostics and drug susceptibility testing (DST) that can be used to detect drug resistance and
facilitate prompt, appropriate treatment plans. This project seeks to address the lack of quick,
specific, and affordable diagnostics through the development of a novel diagnostic technology based
on deoxyribozyme (DNAzyme) sensors for detection of TB and identification of drug resistance.
DNAzyme Sensor Technology for specific detection and differentiation of nucleic acids
Deoxyribozymes (DNAzymes) are catalytically active DNA enzymes that were identified by
in vitro selection [48]. Originally, DNAzymes were designed as a single DNA strand consisting of a
catalytic domain flanked by two substrate recognition arms [49]. In the presence of a specific analyte,
the DNAzyme folds into a catalytically active secondary structure that hybridizes to the analyte
DNA and cleaves a ribonucleotide within the middle of the sequence. However, the length of the
original DNAzyme contributes to its stability, enabling it to hybridize to mismatched sequences and
and therefore preventing its specificity [50]. A binary approach, developed by our collaborator, Dr.
Dmitry Kolpashchikov, divides the DNAzyme into two parts, splitting the catalytic core in half, and
allowing for extremely selective nucleic acid recognition and improved sensitivity of SNP detection
down to a single base substitution [50].
We take advantage of this binary DNAzyme design to create DNAzymes, specific for Mtb
analytes, which will have the ability to distinguish drugR-conferring SNPs. As shown in Figure 1, the
12

binary DNAzyme assay consists of a substrate, analyte, and two sensor strands each containing an
analyte binding arm, half of the catalytic core, and a substrate binding arm. The substrate is a duallabeled synthetic oligonucleotide with a fluorophore on the 5’ end and a quencher at the 3’ end.
When a specific analyte is present, the sensor strands will bind adjacently on the analyte. After
binding the analyte, the sensors will then bind the substrate, reforming the catalytic core, and
subsequently cleave the substrate. This cleavage separates the quencher and the fluorophore
resulting in the production of a fluorescent signal/output [51].

Figure 1: Binary DNAzyme Sensor Assay

Deoxyribozyme sensors can be used for the detection and differentiation of DNA/RNA analytes. This binary
DNAzyme approach splits the catalytic core and allows for the attachment of two short sequences complementary to
the analyte binding arms. In the presence of a DNA/RNA analyte the substrate will be cleaved releasing a
fluorescent/visual output. A) Binary DNAzyme sensor bound to a matched analyte. The analyte binding arms hybridize
to the matched analyte allowing the formation of the catalytic core. This results in cleavage of the substrate and the
production of a fluorescent output. B) Binary DNAzyme sensor in the presence of mismatched analyte. Due to the
presence of a SNP, one of the analyte binding arms will be unable to bind and the catalytic core cannot form. Therefore,
there will be no cleavage of the substrate.

DNAzymes provide several advantages for the specific and sensitive detection of
DNA/RNA analytes. Their catalytic activity allows for activation of approximately eighty substrate
molecules/minute, resulting in signal amplification, unlike the Gene Xpert and molecular beacon
based approaches that are only able to bind a single fluorescent probe/analyte molecule [52]. The
simple design requires only two short DNA strands for each new analyte designed because the
double-labeled reporter substrate is universal for all analytes, reducing the cost of this technology
13

significantly [50, 53]. The combination of a short analyte binding arm and a long analyte binding arm
allows for high sensitivity and selectivity [50]. The presence of a single SNP prevents the binding of
the short analyte binding arm, inhibiting the activation of the DNAzyme and substrate cleavage [50].
Longer oligonucleotides are more likely to bind mismatched DNA. The overall goal is to create an
assay which combines Polymerase Chain Reaction (PCR) and DNAzymes to identify drug resistance
conferring SNPs.
The goals for the project are as follows:
Objective 1: To construct a panel of drug resistant (drugR) nonpathogenic M. bovis BCG.
MDR-TB is dangerous, therefore creating a library of attenuated drugR Mycobacterium bovis
BCG allows us to safely test different DNAzyme sensors on real bacteria. This will be accomplished
by cloning regions surrounding the SNP of interest, making the mutation by QuickChange site
directed mutagenesis, and transforming it into wild-type M. bovis BCG, and selecting for resistance.
This project will focus on drugR conferring mutations in the gyrA gene.
Objective 2: To design a multiplex PCR that will amplify chromosomal regions necessary for TB detection and drug
susceptibility testing (DST)
The overall goal is to use six sets of primers to simultaneously amplify regions of the
genome that will be used later in the multiplex assay for the species-specific detection of TB and
determination of a drug susceptibility profile based on the presence of SNPs. Nucleic acid
amplification (NAA) through PCR is imperative to increase the sensitivity of the assay, because the
current limit of detection is not sensitive enough to detect a single copy on the chromosome. The
PCR conditions will be optimized to achieve optimal specificity, yield, and speed.
14

Objective 3: To design and optimize DNAzyme sensor assays of PCR analytes for detection and DST of Mtb.
The binary design of the DNAzyme assay allows for improved sensitivity of SNP detection.
The sensors will be optimized to balance selectivity and sensitivity. This will be accomplished by
constructing sensors that will discriminate between single SNPs and still produce a good signal. The
limit of detection (LOD) and specificity will be determined. The sensors will be tested on synthetic
analytes, DNA from MDR- and XDR-TB clinical isolates. Combining the DNAzyme sensors with
the multiplex PCR analytes as an optimized assay will enable the rapid, POC detection of drug
resistance.

15

METHODOLOGY
Preliminary Studies
Originally it was thought that single stranded DNA (ssDNA) was the preferred DNAzyme
analyte. To generate the ssDNA analyte, we explored the use of Linear After The Exponential PCR
(LATE-PCR), an asymmetric PCR method which employs unequal concentrations of primers that
run logarithmically until one of the primers run out [54].
Our preliminary data comparing LATE-PCR and conventional symmetric PCR revealed that
the generation of ssDNA is not necessary for detection by DNAzymes (data collected by B.
Rosenkrantz not shown). This is advantageous because asymmetric PCR requires many cycles while
the symmetric approach can be completed in less cycles, meaning less time. As shown in Figure 2,
using the symmetric PCR we were able to detect as few as 50 pg of DNA or 5000 colonies forming

S/B Ratio

units (CFU).
7
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6.45

6.35

5.64
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2.01

1.00

1.47

[Template, pg]

Figure 2: Limit of Detection for DNAzyme detection of Symmetric PCR Analytes.

Serial dilutions of template DNA (x-axis) were amplified by 30-cycles of symmetric PCR and detected by binary
DNAzyme assay. Wild-type specifc rpoB binary sensors were used for the detection of PCR products. The Signal to
Background (S/B) ratio (y-axis) shows that Symmetric PCR (30 cycles) and DNAzyme sensors can detect as little as
~50 pg of DNA or ~5000 CFU. (Data provided by B. Rosenkrantz)
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General Overview of Bacterial Cell Culture
NEB 10-Beta Competent Escherichia coli (E. coli) High Efficiency and electrocompetent
Mycobacterium bovis bacillus Calmette-Guérin (BCG) were used to conduct the experiments for this
project. E. coli was used to amplify plasmids containing genes and DNA fragments PCR amplified
from CDC1551 chromosomal Mtb DNA (20 ng/μL) during cloning [55]. E. coli was also used as a
DNA source for transformation into M. bovis BCG for the development of a panel of
nonpathogenic drug resistant strains.
E. coli was grown up in Luria broth (LB) within a 5 mL culture tube overnight at 37°C,
shaking at 250 revolutions per minute (rpm). When constructing plasmids, 50 μg/mL of the
antibiotic Kanamycin (Kan) was used to select clones containing the vectors of interest.
Creating a panel of drug resistant (DrugR) nonpathogenic M. bovis BCG.
The conservation of DNA between Mtb and the vaccine strain M. bovis BCG has enabled
BCG to be used as a surrogate model for Mtb. Designing a panel of nonpathogenic BCG strains
with specific SNPs that confer distinct drugR will provide a safe template that has the same genetic
background as the real drugR Mtb. The variety of strains containing drugR mutants will be used to
develop an assay that can differentiate individual mutations in a single sample. This project
specifically focuses on the development of a strain containing a drugR conferring gyrA D94G
(GACGGC) mutation.
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Construction of gyrA 94 WT Fragment
First, primers, shown in Table 2, were designed to specifically amplify a 2 kilobase (kb) gyrA
gene fragment using “ApE – A plasmid Editor”, a molecular biology program used for sequence
editing and design, and information from Mycobacterial DNA databases including the “Myco DB xBASE” and TbDb databases [56-59]. Then, amplification of the gyrA gene insert was achieved by
Polymerase Chain Reaction (PCR). The DNA is PCR amplified through a few general steps. First,
the double stranded DNA must be denatured to separate the complementary strands of DNA by
heating it to 95°C [60]. After this primary denaturation, a secondary denaturation is necessary to
ensure complete separation [60]. The third step is an annealing phase in which the temperature
lowers to allow the DNA primers to hybridize to their complementary sites on the DNA template
[61]. The annealing temperature is dependent on the melting temperature (Tm) of the specific
primers used [61]. The primers are then extended using DNA polymerase, an enzyme that catalyzes
the synthesis of new DNA by adding nucleotides onto the annealed primer that are complimentary
to the template DNA [60]. This step is conducted at a temperature optimal for the Phusion® DNA
polymerase, allowing the enzyme to replicate the strand of template DNA. These three steps are
repeated for many rounds to enable the exponential amplification of the DNA of interest. Lastly,
there is a final extension step that allows for the most recent DNA copies to finish replicating [60].
Table 1: Phusion PCR Reaction Settings
Cycle
Number
1

Temperature
(°C)
98
98

Time
(seconds)
30
10

2 (20X)

65

30

3
4

72
72
25

25
60
∞

PCR Step
Initial Denaturation
Secondary Denaturation
Annealing Phase – based on the primers’ melting
temperature.
Initial Extension
Final Extension
Hold Time
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The protocol followed was “PCR Protocol for Phusion® High-Fidelity DNA Polymerase”
[62]. The reaction was ran in a temperature-controlled BioRad thermocycler, allowing for the proper
denaturation and annealing of DNA fragments and enabling the Phusion® enzyme to activate at
specific temperatures. The typical Phusion PCR Cycle used in shown in Table 1. The gyrA specific
primers were used to clone 1.0 kilobase (kb) on both sides of the well-characterized gyrA SNP
location.
The reaction consists of a mixture containing buffers, nucleotides, primers, enzyme, and the
DNA of interest. A typical PCR reaction contains 1.0 μL of template DNA (~20 ng/μL), 1.0 μL of
forward primer (100 ng/μL), 1.0 μL of reverse primer (100 ng/μL), 5.0 μL of 5X GC Buffer, 0.25
μL of Phusion® Enzyme, 0.5 μL of 10mM deoxynucluotides (dNTPs), and 16.25 μL of sterile
water, for a total volume of 25 μL per reaction tube. After amplification, the presence and correct
size of the PCR products were verified using agarose gel electrophoresis. For detection, 5.0 μL of
the PCR product was resolved on 1% agarose gel using TAE buffer and stained with Promega Gelred.
TOPO Cloning
Once the insert containing the amplified wild type (WT) gyrA fragment was obtained, a
plasmid containing the WT sequence encompassing SNPs in the target gene was constructed. This
was accomplished using Zero Blunt® TOPO® cloning, an extremely efficient, 5-minute, one-step
cloning process for the direct insertion of blunt-ended PCR products into a plasmid vector. The
enzyme, Topoisomerase, is linked to the end of the linearized TOPO vector and catalyzes the
ligation of an insert into the vector [63, 64]. This process is efficient because no ligase, post-PCR
procedures, or PCR primers containing specific sequences are required. The TOPO process is also
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advantageous because it allows direct selection of recombinants. The pCR4Blunt-TOPO® plasmid
contains a KanR gene that is used to select for colonies that have incorporated the vector and cells
containing the non-recombinant vector, lacking the resistance, will be killed upon plating [65].
The TOPO Cloning reaction mixture consists of 1.0 μL of the TOPO Cloning vector, 1.0
μL of a salt solution, 2.0 μL of the 2 kb gyrA PCR product, and enough sterile water was added to
bring the final volume up to 6.0 μL. The reaction was incubated for 5 minutes at room temperature
25°C then placed on ice. 2.0 μL of this TOPO Cloning reaction mix was pipetted into a vial of
competent E. coli, mixed gently, and incubated on ice for 30 minutes. After incubating, the cells were
heat shocked at 42 °C for 30 seconds and immediately transferred to ice for recovery. 250 μL of
room temperature SOC medium was added and the tube was capped and shook horizontally at 37°C
for 1 hour. 10-50 μL of the transformation was spread on a Kan antibiotic selective plate and
incubated at 37°C overnight.
Colonies present on the pTOPO-gyrA transformation were PCR screened using M13
forward and reverse primers (100 ng/μL), shown in Table 2, to verify that the insert was present in
the vector. Colony PCR screening involves bacterial lysis and DNA extraction for use in a PCR
reaction. To lyse the bacteria, an isolated colony was labeled, picked from the plate, and added to a
tube containing 20 μL of deionized water (diH2O). The tube was boiled at 100°C for 10 minutes and
centrifuged at 13,000 rpm for 10 minutes to pellet the bacterial debris. 2.0 μL of the resulting
supernatant was used as the DNA template for PCR amplification. Positive colonies were identified
based on the amplification of the band at an anticipated size of 2 kb on a 1% agarose gel.
The positive colonies were picked and grown overnight in 7 mL LB broth containing 7.0
μg/mL Kan to amplify the DNA. The plasmid was then isolated using the Plasmid Mini-Prep
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Protocol. [66] First, the pellet was harvested from the E. coli culture using centrifugation. The
supernatant was discarded and the pellet was suspended in 250 μL of an RNase A Buffer (100
μg/mL) [66]. After adding 250 μL of MX2 Buffer, the tube was gently inverted 4-6 times, and
allowed to incubate at room temperature for 5 minutes until the solution became clear [66]. 350 μL
of MX3 Buffer was then added, the tube was inverted 4-6 times afterwards, and centrifuged at
12,000 rpm for 10 minutes [66]. The supernatant was then transferred to a spin column and
centrifuged at 4,000 rpm for 1 minute and the flow through was discarded. 500 μL of WS Buffer
was added to the spin column and centrifuged for 1 minute, discarding flow through [66]. This was
done twice to wash the mixture. The resulting mixture was centrifuged again to remove residual
ethanol and the column was placed in a new microcentrifuge tube. 50 μL of EB Buffer was added to
the membrane and, after sitting for 5 minutes, the tube was centrifuged at 12,000 rpm for 1 minute
to elute the DNA [66]. The concentration of the resulting mini-prep DNA was measured using a
Nanodrop spectrophotometer and the plasmid was submitted to Genewiz for sequencing to verify
the presence of the 2 kb gyrA fragment. Then glycerol stocks were made to store aliquots of the
DNA by inoculating 500 μL of 50% glycerol with 1.0 mL of the culture. The purified plasmid was
then used as a template for QuikChange mutagenesis to create the gyrA mutant (MT).
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Table 2: Cloning Primers
Cloning primers
Locus
gyrA 2kb
gyrA 94 QuikChange
M13Long

gyrA_2kb_F

ATTGCCGTTCCACGGATC

Size
(bp)
18

gyrA_2kb_R

GGGCGATATCGACGGTCT

18

65

gyrA_QC_F

CGATCTACGGCACCCTGG

18

67

gyrA_QC_R

Primer

Sequence (5' to 3')

Tm
66

CCAGGGTGCCGTAGATCG

18

67

M13L_F

TGTAAAACGACGGCCAGTGAATT

23

68

M13L_R

CAGGAAACAGCTATGACCATGAT

23

64

Product (bp)
2000

?299

Figure 3: Creation of a drugR BCG strain using TOPO Cloning and Site-Directed Mutagenesis

A) gyrA specific primers were used to clone 2 kb fragment containing a gyrA gene and Phusion PCR was used to amplify
the WT gyrA 94 gene of interest within CDC1551 Mtb DNA (20 ng/μL). B) TOPO cloning was used to insert the 2 kb

WT gyrA 94 fragment into the pCR4Blunt-TOPO plasmid containing KanR antibotic resistance marker. C) QuikChange
PCR primers designed to contain the D94G SNP in the center of their sequences were used for the rapid insertion of
the mutation. D) Once the mutation was inserted, the 2 kb PCR Primers were used to amplify the gyrA mutation E)
Butanol Precipitation was used to prepare the MT product for tranformation into BCG. F) After making competent
cells, electroporation was used to transform the 2 kb linear PCR product containing the mutation into WT BCG. G) The
drugR gyrA D94G BCG strain can then be selected for on Ciprofloxicin plates.
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QuikChange Site-Directed Mutagenesis
After successfully TOPO cloning, methodology similar to QuikChange (QC) Site-Directed
Mutagenesis was performed to insert the mutation, as shown in Figure 3. This was accomplished
through a series of steps. First, individual mutagenic primers needed to be designed. Both the
forward and reverse primers were designed to contain the gyrA D94G SNP of interest and to anneal
to the same sequence on opposite strands of the plasmid, as shown in Table 2. The desired mutation
was designed to be in the middle of the primers with ~10-15 nucleotides of the correct sequence on
each side [67]. This reaction followed the protocol by Strategene, in which 2.0 μL of lysate from
colonies containing the gyrA insert was combined with 1.0 μL of each gyrA Mutation QuikChange
forward and reverse primer (100 ng/μL), 0.25 μL of Phusion® polymerase, 0.5 μL of dNTP’s, 5.0
μL of 5X G.C. Buffer, and brought to a final volume of 25 μL using 16.25 μL of diH2O. The
thermocycler PCR settings used for the QuikChange are shown in Table 3.
Table 3: QuikChange PCR Reaction Settings
Cycle
Number
1

Temperature
(°C)
98
98

Time
(seconds)
30
10

2 (30X)

65

30

3
4

72
72
25

90
60
∞

PCR Step
Initial Denaturation
Secondary Denaturation
Annealing Phase – based in the primers’ melting
temperature.
Initial Extension
Final Extension
Hold Time

After performing the QuikChange PCR and verifying the successful amplification and size of
the plasmid on a 1% gel, 1.0 μL of Dpn 1 restriction enzyme was added to the positive
QuikChanged PCR sample, mixed thoroughly, and incubated for 1 hour at 37°C to digest the
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nonmutated (parental) supercoiled dsDNA. Failure to do so results in a high false-positive rate of
pTOPO-gyrA KanR colonies.
After thawing an aliquot of 10-beta Competent E. coli cells, 4.0 μL of digested gyrA Mutant
QuikChanged fragment was added. The cells incubated on ice for 30 minutes and were then heat
shocked for 45 seconds at 42°C. After recovering on ice for 5 minutes, 250 μL of SOC medium was
added and the cells were shaken for 1.5 hours to recover. Then, the entire volume of the
transformation reaction was plated on LB-Kan (50 ug/μL) agar to select for antibiotic resistance and
incubated overnight at 37°C.
The colonies that grew were PCR screened for the insert of interest using M13 forward and
reverse primers and verified on a 1% agarose gel. The PCR products of the E. coli colonies
determined to contain the insert of interest were then prepared for direct sequencing using a PCR
clean-up method that removes excess dNTPs and unincorporated primers from the PCR mixture.
The PCR mixture was incubated at 37°C for 20 minutes in an Exo-SAP mixture consisting of
Antarctic alkaline phosphatase, buffer, exonuclease (20 units/μL), and diH2O, to purify the DNA.
The pure DNA was then sent for sequencing to determine if the correct mutation was present. The
sequence was analyzed using ApE to align the mutated gyrA D94G sequence with the original WT
gyrA sequence to verify that the correct mutation was present.
Transformation into Wild Type BCG
Once the mutated gyrA PCR product was amplified and the sequence was verified, butanol
precipitation was performed to prepare the product for transformation into wild type BCG. This
method removes salt from the ligation buffer to improve transformation efficiency. 10 μL of
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unsaturated n-Butanol was used to precipitate every 1.0 μL of PCR reaction. The mixture was spun
down in at 13,000 rpm for 5 minutes to remove supernatant. The tube was then washed with 100 μL
of 70% ethanol and centrifuged for 5 more minutes to further remove any leftover supernatant. A
speed vacuum was used to dry the pellet and then the pellet was suspended in 10 μL of water. The
concentration of the MT gyrA 2 kb PCR product was then quantified using the Nanodrop
spectrophotometer.
30 mL of M. bovis BCG was pelleted with a 20 mL 10% glycerol wash to rid of excess salt.
This was repeated in smaller and smaller increments until 1.0 mL of BCG was left. Then, 2.0 μg of
gyrA MT DNA was transformed into 100 μL of electrocompetent BCG cells. The electroporation
was accomplished in a 2.0 mL cuvette using the Biorad GenePulser Xcel Microbial System at 250
Volts, 25 μF, and 1,000 Ω. After shocking the cells, they were placed in 5 mL 7H9 and allowed to
recover for 3 days.
After the recovery, 2 mL of electrocompetent drugR BCG was plated on 2 μg/mL
Ciprofloxicin (Cipro) LB agar to select for resistant colonies that have incorporated the SNPcontaining DNA. Colonies were picked at 3 weeks and grown in 5 mL of 7H9 media. Then after
growing for another 3 weeks, a well-established method of nucleic acid isolation from mycobacteria
known as a hexadecyltrimethylammonium bromide (CTAB) treatment, was used to purify the DNA
[68]. Once purified, the DNA product was sent for sequencing to confirm the transformation. The
resulting engineered drugR M. bovis BCG DNA was used as a template in the multiplex PCR which
will later be tested in the DNAzyme assay.
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Design of the Multiplex PCR
The goal of this aim is to develop a multiplex PCR with the ability to simultaneously amplify
six targets, including MTC-specific loci and drugR loci for MDR and XDR-TB, in a single reaction.
The multiplex PCR will be combined with DNAzyme sensors in an assay to specifically detect TB
and identify first and second line drugR in a single sample. PCR amplification is important because
the current limit of detection is not sensitive enough to detect a single copy on the chromosome.
Primer Design
First, primers were designed to specifically amplify the regions of interest. For species
specific identification of TB, two of the primer pairs were designed to target the 16S and 23S rRNA
genes, which are completely identically in BCG and TB. The targeted regions of the 16S and 23S
rRNA genes are hypervariable regions unique to Mtb and therefore are capable of distinguishing TB
and BCG from other members of the Mycobacterium tuberculosis complex (MTC).
Then 4 other primers pairs were designed to target genes associated with drugR. As stated in
the background section, the target genes, gyrA, katG, rpoB, and inhA, were picked to cover the most
common SNPs conferring resistance to first and second line drugs. Mutations in inhA and katG
both confer isoniazid resistance (InhR), a frontline drug for TB. Mutations in rpoB confer rifampinR
(RifR), another first line drug, and gyrA mutations confer fluoroquinoloneR, a second-line drug used
in TB treatment [69]. The 12 multiplex primers that were designed are shown in Table 4 with their
corresponding locus, sequence, nucleotide length, and Tm. The 6 multiplex PCR products are
shown in Table 5 with their description, amplicon size, and mutations. The amplicons were designed
to be approximately 50 base pairs apart to allow for gel resolution.
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Table 4: Multiplex PCR Primers
Locus
inhA
rpoB
16S rRNA
katG
gyrA
23S rRNA

Primer

Sequence (5' to 3')

Size (bp)

Tm

inhA_F1

CCGGAAATCGCAGCCA

16

64

inhA_R1

CGGTTTCCTCCGGTAACCA

19

65

rpoB_F

GTCGCCGCGATCAAGGAGTT

20

71

rpoB_R

CCCTCAGGGGTTTCGATCGGG

21

74

16s_rRNA_F1

GCGATGCCGCGAGGTTA

17

66

16s_rRNA_R1

ACTTCGTCCCAATCGCCG

18

66

katG_F1

ATGGCCATGAACGACGTC

18

65

katG_R1

GTGTATTGCCAAGCGCCA

18

66

gyrA_F1

GACTCGCTCGACCGGATC

18

66

gyrA_R1

GGGCTTCGGTGTACCTCATC

20

66

23s_rRNA_F1

CTCTGCTGCCAAGAAAAGCC

20

66

23S_rRNA_R1

CAGGTCGGAACTTACCCGAC

20

66

Table 5: Multiplex PCR products
Gene
16S rRNA
23S rRNA

Description

Amplicon
Size (bp)

Mutation

239

Multiple

410

Multiple

Species specific TB
detection
Species specific TB
detection

inhA

isoniazidR

149

katG

isoniazidR

299

rpoB

rifampinR

200

gyrA

fluoroquinoloneR

356

Promoter -15 nt
C→T
Codon 315
AGC→ACC
Codon 526
Codon 94
GAC→GGC

Philisa® Thermal Cycler PCR Optimization
Conventional PCR is very time consuming due to slow ramp rates. In an effort to develop a
fast and convenient assay, the Philisa® Thermal Cycler PCR instrument was used to dramatically
reduce amplification time by utilizing extremely quick temperature ramp times and novel reaction
tubes designed for more efficient heat transfer [70]. The rapid thermal cycler is used with a
PhilisaFAST™ DNA polymerase, an enzyme designed to facilitate fast extension times.
27

Each 25 μL reaction contained 1.0 μL of CDC1551 chromosomal Mtb DNA (20 ng/μL), 12
μL of 10 μM Primer Stock, 5.0 μL of FASTBuffer, 4.0 μL of 2.5 μM dNTPs, 0.5 μL of
PhilisaFAST™ Polymerase, and 2.5 μL of diH2O. This 10 uM primer stock contained 1.0 μL of
each of the twelve forward and reverse primers (10 μg/μL) needed for the amplification of the 23S,
16S, inhA, rpoB, gyrA, and katG genes, making 400 nM the final concentration of each primer within
the 25 μL PCR reaction. The multiplex PCR products were verified for clear differentiation and size
on a 2% agarose gel, also using a “no-DNA” control to determine contamination.
The PCR was optimized to obtain maximum specificity and yield. Switching from
conventional PCR methods to the rapid Philisa PCR strategy required optimization of the thermal
cycler parameters to determine the most efficient duration for annealing and number of cycles. To
determine the most efficient annealing temperature that provides a balance between maximum yield
and minimum mis-priming, the annealing temperature was tested in 2 degree intervals. Then the
number of PCR cycles that would yield the most DNA was determined by running reactions with
30, 40, and 50 cycles. To develop the most time efficient protocol, the timing of each step of the
PCR reaction was adjusted to the fastest time that would still amplify the most DNA. The PCR
conditions shown in Table 6 were determined to be the most optimal, producing an efficient
protocol that is just over 30 minutes long. The PCR products were ran on a 2% agarose gel to verify
that they were present at the correct size and roughly equivalent amounts.
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Table 6: Philisa PCR Reaction Settings
Cycle
Number
1

Temperature
(°C)
98
98

Time
(seconds)
30
10

2 (50X)

65

10

3

72
72

10
30

PCR Step
Initial denaturation
Secondary denaturation
Annealing Phase – based in the primers’ melting
temperature.
Final extension
Hold time

DNAzyme Sensor Assay
General Assay Design
The assay was designed to identify the presence of TB and for the detection of MDR SNPs.
The assay designed for gyrA, shown in Figure 4, consists of a substrate, analyte, and two sensor
strands, each containing an analyte binding arm, half of the catalytic core, and a substrate binding
arm. The substrate is a dual-labeled synthetic oligonucleotide with a FAM fluorophore on the 5’ end
and a quencher (Blackhole Quencher 1 (BHQ1)) at the 3’ end.

Figure 4: Schematic diagram of the gyrA 94 wild-type DNAzyme sensor

Binary DNAzymes specific for the WT Mtb gyrA 94 and MT Mtb gyrA D94G analytes were designed. The WT Mtb gyrA
94 analyte strand is shown with the SNP of the MT strand above it. The DNAzyme consists of a substrate (orange),
specific analyte (black), and two sensor strands. Two A strands (Dza) were designed, one complementary to the WT
analyte and the other complementary to the MT, each containing an analyte binding arm (pink), half of the catalytic core
(purple), and a substrate binding arm (purple). Only one version of the B strand (Dzb), complementary to the WT
sequence, needed to be designed, also consisting of an analyte binding arm (red), half of the catalytic core (green), and a
substrate binding arm (green). The Mz substrate is a dual-labeled synthetic oligonucleotide with a FAM fluorophore on
the 5’ end and a quencher (BHQ1) at the 3’ end. When the specific gyrA analytes are present, the sensor strands will bind
adjacently on the analyte. After binding the analyte, the sensors will then bind the substrate, reforming the catalytic core,
and subsequently cleaving the substrate. This cleavage separates the quencher and the fluorophore resulting in the
production of a fluorescent signal/output.
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The substrate is a dual-labeled synthetic oligonucleotide with a FAM fluorophore on the 5’
end and a quencher (Blackhole Quencher 1 (BHQ1)) at the 3’ end. This project specifically focuses
on designing an assay to detect drugR conferring SNPs within the gyrA gene. Sensors for targeted
regions of 16S and 23S ribosomal RNA were chosen for the species-specific identification of Mtb
because their sequences are conserved in both TB and BCG, yet not conserved in other strains of
Mycobacteria. Multiple sensors will increase the specificity of the assay by identifying both the 16S
and 23S rRNA regions in the mycobacteria [15, 71]. The sensors were tested against multiple
templates: a negative control to detect contamination, synthetic analytes that are a perfect match to
the sensors, CDC1551 Mtb DNA, DNA from the gyrA D94G BCG constructed in Objective 1, and
purified DNA containing the gyr94 SNP from XDR-TB, provided by Dr. Susanne Homolka and Dr.
Stefan Niemann at the National Mycobacteria Reference Center in Borstel, Germany.
Sensors were designed to detect the gyrA D94G (GACGGC) SNP and tested for optimal
balance of selectivity and sensitivity. This was accomplished by constructing the short and long
analyte binding arms with different lengths and target Tm’s to allow for sensitivity and selectivity.
The short arm is designed to hybridize to the region overlapping the SNP. The binary DNAzyme
sensors were tested against a matched analyte and a mismatched analyte to determine specificity. The
specificity was optimized by testing the sensors with short binding arms of differing lengths and
Tm’s. After designing sensors for the identification of the gyrA D94G SNP, a LOD assay of the
gyrA WT and MT sensors was completed to determine the sensitivity of the assay. A serial dilution
of the synthetic analytes ranging from 1.0 nM to 12.5 pM, was used in multiple trials. The data was
plotted to calculate a linear trend line and the equation used to determine the LOD was based on the
average of 7 background samples + 3x(the Standard deviation of the 7 background samples). An
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optimized assay combining multiplex PCR with DNAzyme sensors will enable the rapid, POC
detection of drug resistance.
Table 7: Assay Sensors

The color coding and bolding refers to the following. Red: Analyte Binding Arm B. Blue: Analyte Binding Arm A.
Green: Substrate Binding Arm B. Blue: Substrate Binding Arm A. Underline: catalytic core sequence. Bold: location of
SNP. C=MT. T=WT.
GC
Content

#/nts

52.6

19

TGCCCAGGGAGGCTAGCTGGTCCTATCCGGTATTAGACCC

50

20

ACTGGGTCTAATACCGGATAGGACCACGGGATGCATGTCTTGTGGTGGAA

52

50

MSMEG_#_2

ACTGGGTCTAATACCGAATACACCCTGCTGGTCGCATGGCCTGGTAGGGG

58

50

MABS_#_2

ACTGGGTCTAATACCGGATAGGACCACACACTTCATGGTGAGTGGTGCAA

50

50

A_23s_rRNA

AGTAAACAGTCGCTCCTCACTGGTTACAACGAGAGGAAACCTT

48

25

B_23s_rRNA

TGCCCAGGGAGGCTAGCTTCTGCGACCGGATCCCGCTCCCACC

72

25

MTB_23

GGTGGGAGCGGGATCCGGTCGCAGAAACCAGTGAGGAGCGACTGTTTACT

60

50

MSMEG_23

GGCCCAAGCGTGAGTGGGTGGCACAAACCAGTGAGAAGCGACTGTTTACT

56

50

MABS_23

TCCGTGAGCTGAACGAGGTCGCAGAGACCAGTGAGAAGCGACTGTTTACT

54

50

A1_MT_gyrA

TGCCCAGGGAGGCTAGCTCACCAGGGTGCCGTAG

68.8

16

B1_gyrA

CCAGGGCTGGGCCATGCGACAACGAGAGGAAACCTT

77.8

18

gyrA_WT

CTACGACACCCTGGTGCGCATGGCCCAGCCCTGG

70.6

34

gyrA_MT

CTACGGCACCCTGGTGCGCATGGCCCAGCCCTGG

73.5

34

A2_gyrA_64*

TGCCCAGGGAGGCTAGCTCCAGGGTGTCGTAGATCG

61.1

18

A2_gyrA_62*

TGCCCAGGGAGGCTAGCTCCAGGGTGTCGTAGATC

58.8

17

A2_gyrA_61*

TGCCCAGGGAGGCTAGCTCCAGGGTGTCGTAGAT

55.7

16

B2_gyrA

AGGGCTGGGCCATGCGCAACAACGAGAGGAAACCTT

72.2

18

gyrA_WT2

CGATCTACGACACCCTGGTGCGCATGGCCCAGCCCT

66.7

36

gyrA_MT2

CGATCTACGTCACCCTGGTGCGCATGGCCCAGCCCT

66.7

36

Name

Sequence

Substrate:

AAGGTT-FAM-TTCCTCguCCCTGGGCA-BHQ

A_16s_rRNA

CACAAGACATGCATCCCGTACAACGAGAGGAAACCTT

B_16s_rRNA
MTB_#_2
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Experimental Setup
The assay was first designed to test the designed sensors using a background control, WT
synthetic analyte, and MT synthetic analyte. The assay was conducted in a 384-well plate. The
analytes and RNAse free H2O were added directly to the wells first and a master mix containing the
appropriate sensor strands was added last. The total volume of the assay was 60 μL per well. First,
water was added to the wells. 15 μL of water was added to the sensor only (15 nM) background
column and 9.0 μL of water was added to the analyte (1.0 nM) columns. Then 6.0 μL of each 10 nM
synthetic analyte was added to the corresponding well.
Then a master mix containing the substrate and specific adaptor strands was created,
comprising 75% of the total volume of the assay. First, half the total volume in COL 2X Buffer
(consisting of 50 mM HEPES, 50 mM MgCl2, 20 mM KCl2, 120 mM NaCl, 1% DMSO, and 0.03%
Titon-X-100 reagents dissolved in sterile water) added. Then the amount of water needed to make
up 75% of the total volume is calculated by subtracting the volumes of COL 2X Buffer, substrate,
and sensor strands. The volume of substrate (200 nM) and adaptor strands (15 nM) necessary for
the assay is dependent on the total volume of samples. The master mix is then thoroughly mixed
and 45 μL is pipetted to each sample well. The assay is then sealed to prevent evaporation and
incubated for 1 hour at 55°C. Once incubated, the assay is measured in the Biotek Synergy 4
multimode plate reader using specific filter plus dichroic mirror optics at an excitation wavelength of
485/20 and an emission wavelength of 528/20.
Five multiplex PCR reactions were prepared, each utilizing a different DNA template: a
negative “no DNA” control, WT CDC1551 DNA, WT gyrA 94 DNA, gyrA D94G MT BCG, and
the gyrA D94G XDR-TB DNA. These multiplex PCR reactions were tested in an assay with gyrA 94
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and 23S sensors. The gyrA 94 sensors were also assayed with WT and MT analytes and the 23S
species specific sensors were assayed with Mtb, Msmeg, and Mabs synthetic analytes. Based on
preliminary assays using the WT sensor, 25 μL was determined to be the amount of PCR mixture
needed to yield robust signals. By aliquotting 25 μL and 19 μL of sterile H2O respectively, the
background and analyte wells were also brought up to a total volume of 25 μL. The master mix
concentrations were adjusted to a volume of 35 μL to keep the final volume at 60μL.
Data Analysis – S/B ratios
The data was analyzed to determine the performance of the sensors. This was accomplished
by comparing the fluorescent output of the substrate to the fluorescent output of the background in
a signal to background (S/B) ratio. The ability of the WT and MT sensors to differentiate between
the WT and MT analytes, as well as the 5 multiplex reactions: negative “no DNA” control, WT
CDC1551 DNA, WT gyrA 94 DNA, gyrA D94G MT BCG, and gyrA D94G XDR-TB DNA were
analyzed. An optimized assay combining multiplex PCR with DNAzyme sensors will enable the
rapid, POC detection of drug resistance.
Alternative Approaches
Many potential problems involved with designing the panel of drugR BCG strains have been
resolved through the use of the TOPO cloning kit. However, the transformation efficiency of Mtb
and BCG is lower than that of E. coli so introducing an insert with the correct drug resistant
mutation was difficult. The phenotype of the insertion is strong so if the transformation did not
proceed successfully then the plasmid did not survive on the drug resistant selective plate. If we
were unable to design the mutant of interest then we could have selected for the correct
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spontaneous drugR mutation by plating on medium containing the corresponding antibiotic. Then,
the colonies that were able to grow could be sequenced for the target loci to find the drugR strain.
The specificity, equal amplification efficiency, and optimization of the PCR conditions were
challenging due to a number of different variables being involved. Through trial and error it took
multiple optimizations to determine the correct number of cycles, annealing conditions, reagent
concentrations needed for efficient amplification. Contamination of the negative PCR control also
became problematic. This was attempted to be resolved through the use of a biosafety cabinet as
well as DNase and RNAse free reagents and materials. Further multiplex PCR problems that may
present in the future include how well the reaction will amplify DNA directly from clinical sputum
samples and whether it will be sensitive enough.
Designing the DNAzyme sensor assay as well as combining it with the multiplex PCR
proved to be very challenging. Multiple optimization trials were required to determine the most
efficient reagent volumes, assay temperature, and incubation time. Many trials were necessary to
design sensors with optimal signal to background ratios while maintaining high specificity. The
specificity was optimized by designing sensors with different TM’s, lengths, and SNP locations.
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RESULTS
The development of a novel diagnostic involved constructing a surrogate panel of safe drugR
M. bovis BCG strains, designing a 12 primer multiplex PCR, and combining the multiplex PCR with a
DNAzyme assay that can be used to identify TB and detect drugR.
Construction of Safe Surrogate Panel of DrugR M. bovis BCG
In order to safely test the DNAzyme diagnostic assay, a nonpathogenic M. bovis BCG strain
was engineered to contain the drugR-conferring gyrA SNP as detailed in the methods section. Primer
design and PCR amplification of the WT gyrA gene was necessary before the MT strain could be
constructed. To verify the size of the WT gyrA PCR product on an agarose gel, a 1 kb Gene Ruler
was used [72]. 3.0 μL of this standard was loaded into the first lane before the gel was run. An
example of a gel that was imaged, after being stained in Gel Red dye, to verify the presence of the
2000 bp WT gyrA insert is shown in Figure 5. The M13 primers in the second lane were used to
confirm the correct size and the gyrA primers in the third lane show the insert. The upper bands are
likely supercoiled plasmid from the template DNA.
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Figure 5: gyrA PCR Insert

Example of the verification of the WT gyrA fragment PCR product DNA size on an agarose gel using both M13L and
gyrA primers.

After confirming the amplified DNA by running the plasmid on an agarose gel, the PCR
products were TOPO cloned to insert the fragment into the pCR4Blunt-TOPO plasmid. The
plasmid contained a KanR gene that enabled clones which incorporated the vector to be selected for
upon plating on LB-Kan agar. Colony PCR was performed on the colonies that grew to screen for
clones containing the pTOPO-gyrA plasmid. Once colony PCR screened, the positive colonies were
grown overnight in an LB broth containing Kan to amplify the DNA and miniprepped to purify the
DNA. After determining the DNA concentration using a Nanodrop spectrophotometer, the
purified E. coli DNA was sent for sequencing to confirm that the WT gyrA fragment was inserted
into the TOPO plasmid (data not shown).
After successful cloning of the intended gyrA fragment was confirmed, QuikChange SiteDirected Mutagenesis was used to insert the D94G mutation. First, specific primers containing the
SNP in the center of their sequences were designed. Then, the WT DNA was amplified using the
QC primers to amplify the mutant. The bacteria that incorporated the resulting plasmid were
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selected for using the appropriate antibiotic. Colonies that grew were screened and verified on a gel
to ensure that the correct plasmid was present (data not shown). In addition to visualization of the
DNA on a gel, the plasmid was sequenced to confirm that the D94G mutant SNP was inserted into
the WT plasmid. The sequence confirmation of gyrA D94G – TOPO plasmid is shown in Figure 6.

Figure 6: Sequence confirmation of gyrA D94G – TOPO plasmid

The gyr94 – TOPO plasmid was sent for sequencing and then aligned with the WT gyrA 94 sequence (top) to ensure that
the correct mutation was present. The GACGGC mutation is shown in the red box.

After the MT was verified, the PCR amplified and linear DNA fragment transformed into
BCG using electroporation. The BCG that took up the MT fragment was selected for drugR on
Ciprofloxacin antibiotic plates. The colonies that grew were colony PCR screened and verified on a
gel to ensure that the PCR product was successfully double crossed into the BCG chromosome
(data not shown). In addition to visualization of the DNA on a gel, the PCR product was purified
using the PCR clean-up protocol discussed in the methods section and sent for sequencing to
confirm that the drugR SNP was present. The sequence confirmation of the gyrA D94G BCG strain
is shown in Figure 7.

Figure 7: Sequence confirmation of gyrA D94G BCG strain

WT gyrA (top) aligned with MT gyrA D94G BCG (bottom) to verify that the mutation was inserted correctly. The
GACGGC mutation is shown in the red box.
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Optimization of 12 Primer Multiplex PCR
In order to develop an assay to specifically detect TB and identify first and second line drugR
in a single sample, a multiplex PCR with the ability to simultaneously amplify particular targets
including MTC-specific loci and drugR loci for MDR and XDR-TB, was designed in a single
reaction. Nucleic Acid Amplification, like PCR is needed to increase the sensitivity of the diagnostic
assay, because the current limit of detection is not sensitive enough to detect a single copy on the
chromosome. Then the multiplex PCR product was combined with DNAzyme sensors in an assay
to specifically detect TB and identify first and second line drugR in a single sample.
First, 6 primer pairs were designed to specifically amplify the regions of interest. 2 of these
primers were designed to target the hypervariable regions of 16S and 23S rRNA that are only
present in Mtb, enabling the assay to distinguish Mtb and the M. bovis BCG vaccine strain from other
members of the MTC. The other 4 primer pairs were designed to target the gyrA, katG, rpoB, and
inhA, genes which have been shown to contain the most prevalent SNP mutations that lead to first
and second line drugR. The amplicons were designed to be approximately 50 base pairs apart to
allow for gel resolution.
Once designed, the PCR conditions were optimized to achieve optimal specificity, yield, and
speed. This was accomplished using the Philisa thermocycler which facilitates rapid amplification
through implementation of extremely fast ramp times and novel tubes allowing quick heat transfer.
Multiple PCR trials were conducted to determine the most efficient primer concentration and
cycling conditions. The optimized 10 uM primer stock contained 1.0 μL of each of the 12 forward
and reverse primers (10 μg/μL) needed for the amplification of the 23S, 16S, inhA, rpoB, gyrA, and
katG genes, making 400 nM the final concentration of each primer within the 25 μL PCR reaction.
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The annealing temperature was tested in 2° intervals and 65°C was determined to yield the most
PCR product. The number of denaturation-annealing-extension cycles was optimized through 10
cycle interval trials and 50 cycles was shown to yield the most robust results. The multiplex PCR
products were verified for clear differentiation and size on a 2% agarose gel, also using a “no-DNA”
control to determine contamination. Figure 9 is an example gel image of the optimized 12 primer
multiplex using each individual primer pair.

Figure 8: 12 Primer Multiplex PCR for drugR detection with DNAzyme assay

Agarose gel verification of the 12 Primer Multiplex PCR product compared to the PCR products of the 6 individual
primer pairs.

Creation of DNAzyme Sensor Assay
To enable the rapid POC detection of drug resistant TB, a DNAzyme sensor assay of PCR
analytes for the detection and DST of Mtb was designed and optimized. The sensors, shown in
Table 7 of the methods, were designed to detect the gyrA D94G (GACGGC) that this project
specifically focuses on and then tested for optimal balance of selectivity and sensitivity. This was
done by constructing the short and long analyte binding arms with different lengths and target Tm’s
to allow for optimal sensitivity and selectivity. Once designed, the binary DNAzyme sensors were
first tested against a matched analyte and a mismatched analyte to determine specificity. The
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specificity was optimized by testing the sensors with short binding arms of the DNAzyme with
differing lengths and Tm’s.
The first round of gyrA sensor strands (A1 WT and A1 MT, and WT B1) tested were
designed with analyte binding arms of about 16-18 nucleotides in length. The SNP was located in
the sequence hybridized by the A analyte binding arm. Since the A strand was used for SNP
discrimination, both a WT and MT A strand were designed and only a single WT B strand was
needed. The A1-MT analyte binding arm was designed to contain the SNP near its center. The
efficacy of the sensors was determined by comparing the signal of the specific strand to that of the
nonspecific strand, this is referred to as the specificity ratio. A sensor is deemed efficient if it can
yield a high specific signal and keep the nonspecific signal under 2. Through several assay trials, the
A1-MT sensor strand, shown in Figure 10, proved to yield a high specificity ratio of about 4.3. This
is found by dividing the average specific MT signal, 6.26, by the average nonspecific WT
background signal, 1.45. However, new strands needed to be designed because the A1-WT sensor
strand was not specific, having a low specificity ratio (data not shown). The specificity was
optimized by shifting the sequences of the A and B analyte binding arms down 3 nucleotides and
then 3 specific A strands, now referred to as A2, were designed by trimming the length of the
shifted analyte binding arm. The newly designed A2 analyte binding arms were 18, 17, and 16
nucleotides long and had corresponding Tm’s of 64, 62, and 61°C, shown in Figure 10. The A2 WT
sensor with the highest Tm’s, 64°C, had the worst specificity, yielding a specificity ratio of
approximately 1.56, found by dividing the average specific WT sensor signal, 8.02, but the average
nonspecific MT signal, 5.12. The A2 WT 62 sensor had an average specific WT signal of 6.91 and an
average nonspecific MT signal of 3.09, yielding a specificity ratio of 2.2. The sensor with the shortest
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analyte binding arm and lowest Tm yielded the best specificity ratio of approximately 3.2: found by
dividing the average specific WT signal, 6.28, by the average nonspecific MT signal, 1.98. This shows
that shortening the arm, and therefore lowering the Tm, gave better specificity with only minimal
loss of signal.
The A1-MT and B1 strands were used in the assay to identify the MT and the A2-WT and
B2 strands were used in the assay to identify the WT. The combination of these two sensor sets
yielded the most efficient assay with the highest signal.

Signal/Background Ratio

gyrA 94 Sensor Optimization
12.00
10.00
8.00
6.00
4.00
2.00
0.00
WT
MT

A2 - 64
8.02
5.13

A2 - 62
6.91
3.09
WT

A2 - 61
6.28
1.96

A1 - MT
1.45
6.26

MT

Figure 9: Optimization of gyrA 94 WT sensor

The specificity of the sensor strands were optimized by testing different analyte binding arm lengths and Tm’s. A1 refers
to the first set of sensors developed and, through multiple trials, the A1-MT yielded a high, match to mismatch
specificity ratio of approximately 6: 6.26(MT)/1.45(WT). The A1-WT sensor (not shown) proved to be nonspecific, with
a low specificity ratio so a new set of sensors were designed by shifting the sequences by 3 nucleotides. New WT
sensors, referred to as A2 were designed and optimized by trimming the analyte binding arm from 18 to, 17, and 16 with
corresponding Tm’s of 64, 62, and 61°C (as shown above). A trend appeared in which the sensor’s specificity ratio
increases as the length and therefore Tm, decreases. From the 8.02/5.13 specificity ratio of WT A2-64, 6.91/3.09 of WT
A2-62, to the highest specificity ratio: 6.28/1.96 of the WT A2-61 sensor.

After designing and optimizing sensors for the identification of the gyrA 94 SNP, a LOD
assay of the gyrA WT and MT sensors was conducted using synthetic analytes to determine the
sensitivity of the assay. A serial dilution of the synthetic analytes ranging from 1.0 nM to 3.125 pM,
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was tested in multiple trials. The data was plotted to calculate the linear trend line, shown in Figure
10, and the equation used to determine the LOD was based on the average of 7 background samples
+3(the Standard deviation of the 7 background samples).
The calculated LOD is higher than expected. This may be due to variability in the S/B ratios
of the 7 background samples (Data not shown). The LOD for the WT 61 sensor was calculated
using the equation above to be 170 pM with an R2 value of 0.97. The signal of each reaction
compared to the no analyte background control, known as the substrate to background (S/B) ratio,
was used to analyze the data. At a concentration of 1 nM, the WT 61 sensor produced an average
S/B ratio 3.95. At 500 pM, the S/B ratio decreased to an average of 2.8 and then decreased to 1.75
at 250 nM. The S/B decreased to 1, unable to distinguish the analyte signal from the background, at
an analyte concentration of 50 pM. The LOD for the WT 62 sensor was calculated to be 212 pM
with an R2 value of 0.98. At a concentration of 1 nM, the WT 62 sensor produced an average S/B
ratio 4.0. At 500 pM, the S/B ratio decreased to an average of 2.7 and to 1.9 at 250 nM. The S/B
decreased to 1 at an analyte concentration of 50 pM. Further optimization of the WT sensors is
needed for a more specific assay.
The LOD for the MT sensor was calculated to be 108 pM with an R2 value of 0.98. At a
concentration of 1 nM, the MT sensor produced an average S/B ratio 6.3. At 500 pM, the S/B ratio
decreased to an average of 4.5. At analyte concentrations of 250 and 50 pM, the S/B remained at
2.9 and then plateaued to 1 at an analyte concentration of 50 pM.
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Figure 10: gyrA 94 WT LOD

Serial dilutions of the gyrA WT 61, WT 62, and MT synthetic analytes, from 1 nM to 3.125 pM (x axis), were ran with
WT and MT-specific binary sensors and detected by the binary DNAzyme assay. The Average S/B ratio (y axis) shows
that the MT DNAzyme sensor can detect as low as 108 pM of analyte and the WT 61 and WT 62 DNAzyme sensors
can detect as low as 170 and 212 pM of analyte, respectively.

The binary DNAzyme assay was tested with the multiplex PCR after verifying their
successful PCR amplification on a 2% gel (data not shown). To determine the efficacy of our
multiplex PCR-DNAzyme DST assay, ability to detect drugR SNPs in the multiplex PCR, the gyrA
94 Multiplex PCR analytes from WT CDC1551, gyrA 94 BCG MT DNA, and gyrA 94 XDR-TB
DNA was analyzed using WT and MT gyrA 94 sensors and 23s rRNA sensors. A negative “no
DNA” multiplex PCR analyte was also used to verify contamination. The results are shown in
Figures 11-13.
Figure 11 shows the S/B ratios of the gyrA WT sensor, specifically the optimized A2-61°C
WT sensor (background data not shown). The negative control, which was expected to have a low
S/B ratio of approximately 2, was higher than expected due to contamination of the multiplex “no
DNA” control. The WT sensor reacted with the gyrA 94 Multiplex PCR analytes from WT
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CDC1551 as predicted, yielding a high S/B ratio of 7.1. This was expected because the WT sensors
are specific for the WT template. The WT sensor did not produce as much signal when combined
with the Multiplex PCR analytes from the gyrA 94 BCG MT DNA, however it still produced an
average S/B ratio of 5.3. This nonspecific signal is higher than expected but may be due, in part, to
the contamination shown in the negative control. The WT sensor produced a lower signal when
combined in the assay with the gyrA 94 XDR-TB DNA Multiplex PCR analytes. The lower signal
was expected because the WT sensor is not specific for the gyrA MT. The S/B ratio of 4.04 may also
be due to the contamination that is shown in the negative control. When assayed with the WT
synthetic analyte (1 nM), the WT sensor produced a moderate S/B ratio of 4.7. Since the sensor was
designed to be specific for the WT analyte, the S/B ratio was expected to be higher. The WT sensor
produced little signal when combined with the MT synthetic analyte. The low S/B ratio of 2.2 was
expected because the WT sensor is not specific for the MT analyte.
The difference in the S/B ratio of the WT and Mt analytes indicates that the sensor can
successfully differentiate between the pure analytes. However, the contamination of the negative “no
DNA” is problematic and the high signal from the gyrA D94G BCG MT and gyrA D94G XDR-TB
multiplex PCR analytes indicate that further optimization of the WT sensor is necessary to
distinguish the multiplex PCR analytes.
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Figure 11: gyrA WT Sensor S/B Ratios

Negative Control: “no DNA” Multiplex PCR control. WT CDC: gyrA 94 Multiplex PCR analytes from WT CDC1551.
gyrA D94G BCG: gyrA 94 Multiplex PCR analytes from gyrA D94G BCG MT DNA. gyrA D94G XDR-TB: gyrA D94G
XDR-TB DNA Multiplex PCR analytes. WT syn (1 nM): WT synthetic analyte with a final concentration of 1 nM. MT
syn (1 nM): MT synthetic analyte with a final concentration of 1 nM.

Figure 12 shows the S/B ratios of the optimized A1-MT gyrA sensor. The negative multiplex
PCR analyte, produced a low S/B ratio of 1.36. This was expected because no signal should have
been seen from the “no DNA” control. The MT sensor also produced a low signal when assayed
with the gyrA 94 Multiplex PCR analytes amplified from WT CDC1551. The S/B ratio of 1.54 was
expected because the sensor is not specific for the WT template. When assayed with the multiplex
PCR analytes amplified from the gyrA D94G BCG MT DNA, the MT sensor produced a S/B ratio
of 7.42. This high signal was expected as the MT sensor was designed to be specific for the SNP.
The MT sensor also produced a high signal when assayed with the gyrA D94G XDR-TB DNA
Multiplex PCR analytes. The S/B ratio of 7.43 was expected because the gyrA D94G XDR-TB
DNA also contains the SNP that the MT sensor is specific for.
When assayed with the WT synthetic analyte (1 nM), the MT sensor produced a S/B ratio of
1.18. The low S/B ratio was expected because the sensor is not specific for the WT analyte. The MT
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sensor produced a high signal when combined with the MT synthetic analyte. The high S/B ratio of
5.35 was expected because the MT sensor was designed to be specific for the MT analyte. The high
S/B ratios of the WT (both CDC1551 and synthetic) multiplex’s and the low S/B ratios of the MT
(5.1, 1598, and synthetic) MT multiplex analytes indicate that the sensor can successfully distinguish
the SNP.
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Figure 12: gyrA MT Sensor S/B Ratios

Negative Control: “no DNA” Multiplex PCR control. WT CDC: gyrA 94 Multiplex PCR analytes from WT CDC1551.
gyrA D94G BCG: gyrA 94 Multiplex PCR analytes from gyrA D94G BCG MT DNA. gyrA D94G XDR-TB: gyrA D94G
XDR-TB DNA Multiplex PCR analytes. WT syn (1 nM): WT synthetic analyte with a final concentration of 1 nM. MT
syn (1 nM): MT synthetic analyte with a final concentration of 1 nM.

Figure 13 shows the S/B ratios of the species specific 23S rRNA sensor. The negative
control, which was expected to have a low S/B ratio below 2, was slightly higher than expected due
to contamination of the multiplex “no DNA” control. The S/B ratios of the species specific 23s
rRNA are expected to be similar and high amongst the WT gyrA 94 CDC1551, gyrA D94G BCG
MT, and gyrA D94G XDR-TB Multiplex PCR products, and Mtb synthetic (1 nM) analytes because
they are all members of Mtb and contain identical 23S rRNA sequences. This similarity is seen in the
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results with the S/B ratios of 4.25, 4.89, 3.82, and 6.06. The slight variability that is present may be
due to differences in PCR amplification. The slightly higher Mtb synthetic analyte S/B ratio of 6.06
is because the sensors were designed specifically for that analyte therefore should produce the
highest signal. M. absessus (Mabs) and M. smegmatis (Msmeg) are not members of Mtb and lack the
species identifying 23S rRNA, therefore they were expected to yield a low S/B ratio. When assayed
with the Mabs and Msmege synthetic analyte (1 nM), the WT sensor produced very low S/B ratios of
1.15 and 1.02, respectively.
The difference in the S/B ratio of Mtb versus Non-Mtb (NTM) indicates that the sensor can
successfully differentiate between the species. However, the contamination of the negative “no
DNA” is problematic and further optimization is necessary to yield a more accurate control.
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Figure 13: 23S rRNA Sensor S/B Ratios
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Mtb syn (1 nM): Mtb synthetic analyte with a final concentration of 1 nM. Mab syn (1 nM): Mabs synthetic analyte with a
final concentration of 1 nM. Msm syn (1 nM): Msm synthetic analyte with a final concentration of 1 nM.
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DISCUSSION
Due to the rise of MDR-TB and XDR-TB worldwide, the need for new diagnostic assays
that are able to efficiently detect Mtb while synonymously identifying drug resistance has increased.
One-third of the world’s population is currently living with TB and about 9 million more people
became infected annually. The TB infection causes over 1.3 million deaths each year. TB’s ability to
be transmitted through breathing in the aerosolized droplets coughed up by someone with active
disease has given it the potential to unknowingly spread to others at a disastrous rate. In order to try
to address this problem, this project was aimed to develop a novel diagnostic technique combines
DNAzyme sensor assays with multiplex PCR analytes to enable the rapid, POC detection of
tuberculosis and identification of multi-drug resistance.
The aims of this project were to construct a BCG strain with gyrA D94G drug resistant
SNPs, develop a multiplex PCR that amplifies chromosomal regions necessary for TB detection and
DST, and design SNP specific binary sensors to enable the identification of any drug resistant Mtb
mutations present. PCR amplification and TOPO cloning allowed the amplification and insertion of
the WT gyrA gene, before it was able to be mutated to contain the SNP of interest using a
QuikChange mutagenesis method. Then the gyrA gene containing the resistance-conferring SNP was
transformed into the M. bovis BCG vaccine strain using electroporation. Construction of a validated
panel of BCG with the gyrA D94G drug resistant SNP allowed us to have safe template strains to
test the Multiplex assay. A 12 primer multiplex PCR that amplifies 6 chromosomal regions necessary
for TB detection and DST was designed. After multiple trials, a 30 minute PCR reaction with 50
cycles provided the most efficient amplification. While contamination of the negative “no DNA”
proved to be problematic, the multiplex was successfully optimized for the amplification of 6 targets
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in a single reaction for use in the DNAzyme Assay. The development of gyrA D94G SNP specific
binary sensors that are able to identify the drug resistant Mtb were designed for use in the DNAzyme
assay. The sensors were optimized for specificity and high signal to background ratios and then the
LOD and their ability to detect multiplex PCR analytes were tested in multiple assays. While the MT
sensors proved to be specific while still maintaining a high signal, the WT sensors require further
optimization
Future work for this project includes the development of BCG strains containing other
drugR conferring SNPs. This will enable us to safely optimize the DNAzyme diagnostic assay.
Further testing of SNP specific sensors that will be able to discriminate between the SNPs and still
produce a high signal. Other work includes the development of a multi-color assay with specific
colors detecting specific resistances in a single tube. This way we might be able to give a molecular
profile of the specific drugR present.
The final outcome of this project has led to the development of a novel method for
detecting TB and identifying the drugR present. With the emergence of MDR-TB, this project has
furthered the development of future drugR diagnostic assays that will enable the prompt and specific
diagnosis of TB allowing for the implementation of an effective treatment regimen that will
ultimately lessen transmission and control the emerging global threat of TB.
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